
==== Front
Neoplasia
Neoplasia
Neoplasia (New York, N.Y.)
1522-8002
1476-5586
Neoplasia Press

S1476-5586(24)00079-4
10.1016/j.neo.2024.101037
101037
Original Research
Metformin combined with cisplatin reduces anticancer activity via ATM/CHK2-dependent upregulation of Rad51 pathway in ovarian cancer
Zhang Jingjing ab1
Zhou Ping c1
Wu Tiancheng ab1
Zhang Liping d1
Kang Jiaqi e1
Liao Jing bf
Jiang Daqiong ab
Hu Zheng huzheng@whu.edu.cn
ab⁎
Han Zhiqiang hanzq2003@tjh.tjmu.edu.cn
gh⁎
Zhou Bo bozhou2208@whu.edu.cn
ab⁎
a Department of Gynecologic Oncology, Zhongnan Hospital of Wuhan University, 169 Donghu Road, Wuhan, Hubei 430071, China
b Women and Children's Hospital Afiliated to Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430071, China
c Gynecological Department, Dongguan Maternal and Child Hospital, Dongguan, Guangdong 523000, China
d Department of Social Medical Development, Zhongnan Hospital of Wuhan University, 169 Donghu Road, Wuhan, Hubei 430071, China
e Department of gynaecology and obstetrics of People's Hospital of Zhongxiang City, Hubei 431900, China
f Department of Gynecology, Zhongnan Hospital of Wuhan University, 169 Donghu Road, Wuhan, Hubei 430071, China
g Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China
h Department of Obstetrics and Gynecology, Shanxi Bethune Hospital, Taiyuan, Shanxi 030032, China
⁎ Corresponding authors. huzheng@whu.edu.cnhanzq2003@tjh.tjmu.edu.cnbozhou2208@whu.edu.cn
1 These authors contribute equally to this work.

13 8 2024
11 2024
13 8 2024
57 10103728 6 2024
25 7 2024
28 7 2024
© 2024 The Authors. Published by Elsevier Inc.
2024

https://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Ovarian cancer (OC) is the deadliest malignancy of the female reproductive system. The standard first-line therapy for OC involves cytoreductive surgical debulking followed by chemotherapy based on platinum and paclitaxel. Despite these treatments, there remains a high rate of tumor recurrence and resistance to platinum. Recent studies have highlighted the potential anti-tumor properties of metformin (met), a traditional diabetes drug. In our study, we investigated the impact of met on the anticancer activities of cisplatin (cDDP) both in vitro and in vivo. Our findings revealed that combining met with cisplatin significantly reduced apoptosis in OC cells, decreased DNA damage, and induced resistance to cDDP. Furthermore, our mechanistic study indicated that the resistance induced by met is primarily driven by the inhibition of the ATM/CHK2 pathway and the upregulation of the Rad51 protein. Using an ATM inhibitor, KU55933, effectively reversed the cisplatin resistance phenotype. In conclusion, our results suggest that met can antagonize the effects of cDDP in specific types of OC cells, leading to a reduction in the chemotherapeutic efficacy of cDDP.

Keywords

Metformin
Cisplatin resistance
Ovarian cancer
ATM/CHK2
Rad51
==== Body
pmc1 Introduction

Ovarian cancer (OC) is the eighth most common cause of cancer death and the leading cause of death from gynecological malignancies worldwide, the onset of ovarian cancer is insidious and often diagnosed at advanced stages, with the five-year survival rates below 45 % [1,2]. In advanced stage (stage III and IV) disease, 5-year overall survival rates decline sharply to approximately 30 % [3]. The standard treatment protocol for advanced OC involves cytoreductive surgery combined with platinum-based adjuvant chemotherapy [4,5]. Resistance to chemotherapy, exacerbated by repeated chemotherapy cycles, is a significant cause of mortality in OC patients [2]. Chemotherapy-resistant OC has a very poor prognosis and lacks effective treatments, presenting a critical clinical challenge that urgently needs addressing [6].

Cisplatin (cDDP) induces the formation of DNA cross-links, which are subsequently converted by the cellular machinery into nuclear DNA double-strand breaks (DSBs) [7,8], and it enhances DNA damage during the DNA homologous recombination repair (HRR) process, thereby diminishing DNA repair capabilities and inhibiting the progression of OC [9]. OC cells evade cDDP-induced cell death through various mechanisms, including the cell metabolism pathway, oxidative stress pathway, and cell cycle regulation pathway. Additionally, they employ HRR and homologous DNA templates to repair DNA damage caused by cDDP. The DNA repair function in OC cells remains continuously active, leading to the development of cDDP resistance [10]. Other drugs, such as paclitaxel, are used in combination treatments for cDDP-resistant OC, but their effectiveness is limited [11]. Recently developed targeted drugs for OC are costly and not affordable for all patients [12]. Combining cDDP-based chemotherapy with other effective drugs is an alternative worth considering. However, the efficacy of combined therapies against cDDP resistance necessitates a thorough and detailed assessment due to their variable results and substantial impact on treatment effectiveness.

Metformin (met) is a first-line classic drug for treating type Ⅱ diabetes and has demonstrated antineoplastic effects in epidemiological and laboratory studies [13,14]. Met alone can significantly reduce the number of cancer stem cells in OC tissue and inhibit the growth and metastasis of OC cells [15,16] However, the impact of met combined with cDDP on OC therapy remains unclear. Some studies have shown that met not only enhances the therapeutic effects of cDDP on certain tumors, such as locally advanced head and neck squamous cell carcinoma and osteosarcoma [[17], [18], [19]], but also mitigates adverse side effects of cDDP, including acute renal injury, cognitive impairment, and brain damage [20,21]. Conversely, other studies have suggested that met promote cDDP resistance in gastric cancer and antagonize the cytotoxicity of cisplatin towards various cancer cell lines such as U251 human glioma, C6 rat glioma, SHSY5Y human neuroblastoma, L929 mouse fibrosarcoma, and HL-60 human leukemia [22,23]. There has also been retrospective data supporting combination of metformin, digoxin, simvastatin as reasonable directions for anticancer therapy. In this work, cDDP was not identified as affecting benefit or resistance in combination with chemotherapy although combination with taxanes or gemcitabine was shown to be improve response when in combination with metformin and/or combined therapies of digoxin, simvastatin and metformin [24]. This study aims to explore the effects of met combined with cDDP on the chemotherapeutic efficacy of OC and its molecular mechanisms both in vitro and in vivo.

2 Material and methods

2.1 Cell culture

The cDDP-resistant OC cell line (C13*) was gifted from Professor Benjamin K. Tsang in the Ottawa Health Research Institute, Ottawa, Canada [25]. The human OC cell line A2780 was purchased from American Type Culture Collection (ATCC; Manassas, VA, USA). Cells were cultured in Macoy'5A medium (Gibco, Carlsbad, CA, USA) supplemented with 10 % fetal bovine serum (FBS; Gibco), penicillin (100 units/ml) and streptomycin (100 µg/ml) at 37˚C in a humidified atmosphere containing 5 % CO2.

2.2 Reagents

The met (S1741) and KU55933(SC9136) were bought from Beyotime Biotechnology (Shanghai, China), cDDP (232120) was purchased from Sigma-Aldrich (St. Louis, MO, USA).

2.3 Western blot

Western blot analysis was performed as previously described [26]. The primary mouse monoclonal anti-β-actin (1:1,000, ab8226), anti-Gapdh (1:1,000, ab8245), anti-p-CHK2 (phospho T383, ab59408, 1:1,000) and rabbit monoclonal anti-Bcl2(1:2,000, ab182858), anti-p-ampk (1:1,000, ab133448), anti-p-mTOR (phospho S2448, 1:2,000, ab109268), anti-p-ATM (phospho S1981, 1:1,000, ab315019) were obtained from Abcam (Cambridge, UK). The primary rabbit monoclonal anti-c-caspase-3 antibody (1:1,000) was purchased from Cell Signaling Technology (USA). The primary rabbit polyclonal anti-cleaved-PARP (1:1,000) and anti-Rad51 (1:1,000) was purchased from Epitomics Corp (Burlingame, CA, USA). Mouse monoclonal anti-γ-H2AX (Ser139) antibody (1:800) was purchased from Millipore Corp (USA).

2.4 Immunohistochemical staining and analysis

Immunohistochemical staining was performed according to standard procedures. The tissues were stained with rabbit polyclonal anti-Ki-67 antibody (1:200, ab15580, Abcam), rabbit monoclonal anti-Rad51 antibody (1:100, Epitomics Corp), rabbit monoclonal anti-p-ATM (phospho S1981, 1:200, ab315019, Abcam,), mouse monoclonal anti-p-CHK2 (1:200, ab59408, Abcam), rabbit monoclonal anti-c-caspase-3 antibody (1:100, Cell Signaling Technology) overnight at 4℃. We treated the negative controls as the same way without the primary antibody. Finally, only the staining of Ki-67, Rad51, p-ATM, p-CHK2, and c-Caspase3 in tumor cells was regarded as positive. The results for the protein level were counted by the staining score, as the score were measured based on the percentage of positively stained cells (score 0, no positive cell; score 1, ≤10 % positive cells; score 2, 11 %-25 % positive cells; score 3, 26 %-50 % positive cells; and score 4, ≥51 % positive cells) and staining intensity (scores 0 and 1 were categorized as low expression, and scores 2, 3 and 4 were categorized as high expression). All score was determined separately by two independent experts simultaneously under the same conditions.

2.5 Immunofluorescence (IF) for functional HR

Rad51/γ-H2AX IF was used as a functional HR assay because one γ-H2AX focus corresponds to one DSB, and nuclear Rad51 foci formation is a marker of functional HR [6]. The IF for functional HR was performed as previously described [27]. Briefly, mouse monoclonal anti-γ-H2AX (Ser139) antibody (1:800, Millipore Corp) and rabbit monoclonal anti-Rad51 (1:100, Epitomics Corp) were incubated at 4℃ overnight, followed by secondary antibodies conjugated to FITC or CY3. Images were acquired using a laser scanning confocal microscope (Olympus). The signal intensity of foci per cell was calculated by subtracting the mean signal in untreated nuclei. γ-H2AX and Rad51 foci were quantified in at least 50 nuclei from three different fields of each coverslip using Image J.

2.6 Alkaline single-cell agarose gel electrophoresis (COMET) assays

Alkaline comet assays were performed with the Trevigen's Comet Assay Kit as described in the manufacturer's instructions. Briefly, cell suspensions were embedded in LMAgarose and deposited on comet slides. The slides were incubated 1h at 4°C in lysis solution, followed by immersing slides in freshly prepared lkaline unwinding solution (pH > 13) for 20 min at RT in the dark. Electrophoresis was carried out for 30 min at 21 V in electrophoresis solution (pH > 13). Slides were then stained with SYBR Green I. DNA strand breakage was expressed as “comet tail moment”. Tail moment was measured for 100 cells per sample at least and average damage remaining of at least 3 independent experiments was calculated. Tail DNA content was analysed with Cometscore1.5 software.

2.7 Animal experiments

4-6-weeks female nude BALB/c mice, which from Beijing HFK Bioscience Co., Ltd. were housed and maintained in laminar flow cabinets under specific pathogen-free condition. C13* cells (5×106) were resuspended in 50 μL of phosphate-buffered saline and were injected into the mice via intraperitoneal. One week after tumor cell injection, mice were randomly separated into treatment groups. Firstly, we treated the mice as the following:(a) cDDP, n=5; (b) met + cDDP, n=5. For KU55933 treatment, we treated the mice as the following: (a) met + cDDP, n=5; (b) met+cDDP+KU55933, n=5. met (20 mg/kg, dissolved in physiological saline) was given intraperitoneally daily for 28 consecutive days; cDDP (5 mg/kg, dissolved in physiological saline) was given intraperitoneally every 4 days for 28 days; KU-55933 or excipient (10 % dimethyl sulfoxide saline) 5 mg/kg was given 30 min min before cDDP injection and 1, 2, 4, 7 and 14 days after cDDP injection. Tumor xenografts each group were collected at the end point.

2.8 Apoptosis assay

Cells were collected using 0.25 % trypsin and subsequently washed with PBS. After centrifugation, the cells underwent fixation in 80 % ice-cold ethanol and were maintained at -20°C overnight. Subsequently, they were treated with 500 μL of buffer containing 50 μg/mL propidium iodide (PI) and 20 μg/mL RNase, and incubated for 30 min min. The apoptotic cells were analysed using a FAC-Scan flow cytometer, and the results were processed with Cell Fit software. This experiment was conducted in triplicate.

2.9 Statistical analysis

SPSS 22 (SPSS Science Inc., Chicago, Illinois), Excel (Microsoft, Redmond, WA, USA) and Prism 7.0 (GraphPad Software, La Jolla, CA, USA) were used to perform data analysis. Quantitative data were expressed as the mean ± S.E.M. The means were calculated at least from three independent experiments. Student's two-tailed t-test was used to compare the mean values of two groups as applicable, data were evaluated with one-way analysis of variance (ANOVA) for studies involving more than two groups Statistical significance was designated at P < 0.05.

3 Results

3.1 Met combined with cDDP led to a reduction in apoptosis in C13* and A2780 cells

Initially, we assessed the apoptosis of C13* and A2780 cells after treatment with either met, cDDP, or their combination. Flow cytometry results indicated that both met and cDDP alone significantly increased apoptosis in C13* and A2780 cells (Fig. 1A, P<0.05). However, when met and cDDP were combined, the apoptosis in these cells was reduced (Fig. 1A, P<0.05). Furthermore, the results were consistent regardless of whether the cells were pre-treated with met or cDDP, indicating that the order of administration did not impact the experimental outcomes. (Fig. 1B, P<0.05).Fig. 1 Effects of met and cDDP alone or both on apoptosis of C13* and A2780 cells. (A) C13* cell. met, 10 μM; cDDP, 100 μM. (B) A2780 cells. met, 10 μM; cDDP, 50 μM. After the two kinds of cells were treated for 48 hours, the apoptosis was detected by flow cytometry. Mean ± SEM, n = 3. *P<0.05, **P<0.01, ***P<0.001 vs. control. Con, control; met, metformin; cDDP, cisplatin.

Fig. 1

3.2 Met combined with cDDP alleviated the cDDP-induced injury in OC cells and induced resistance to cDDP

We assessed apoptosis and the expression of DNA damage-related genes in A2780 and C13* cells after exposure to met alone or in combination with cDDP. Caspase-3 and Bcl-2 are critical regulators of apoptosis [28,29], γ-H2AX is one of the markers for DSBs [30], while Poly (ADP-ribose) polymerase (PARP) and Rad51 are critical DNA repair enzymes [31,32]. Additionally, ampk and mTOR are closely associated with the progression of OC [33,34]. In A2780, met alone did not significantly affect the protein levels of cleaved Caspase-3 (c-Caspase3), Bcl-2, γ-H2AX, or phosphorylated PARP (p-PARP). However, it upregulated Rad51 and phosphorylated ampk (p-ampk) protein levels while decreasing phosphorylated mTOR (p-mTOR) levels. The combination of met and cDDP significantly decreased the protein level of the c-Caspase3 and γ-H2AX caused by cDDP (Fig. 2A). In the C13* cell, met alone did not change the protein levels of c-Caspase3, Bcl-2, and p-PARP, but it increased γ-H2AX protein expression. When treated with met combined with cDDP, or pre-treated with met for 12 hours followed by cDDP for 48 hours, the protein expression of c-Caspase3/Bcl-2 and DNA damage-related genes, including γ-H2AX, decreased, while Rad51 protein expression increased (Fig. 2A). Furthermore, we assessed Rad51 protein expression in C13* cells treated with met combined with cDDP using IF. The results indicated that met alone reduced Rad51 protein expression, while met combined with cDDP lessened the inhibitory effect of cDDP on Rad51 protein expression (Fig. 2C). The comet assay showed that met combined with cDDP reduced the DNA DSBs induced by cDDP (Fig. 2D). In conclusion, these findings suggested that met combined with cDDP reduced apoptosis and DNA damage induced by cDDP, lessened the cytotoxicity of cDDP in A2780 and C13* cells, and led to cisplatin resistance, possibly due to an increase in Rad51 levels. The sequence of met administration did not affect its impact on cDDP.Fig. 2 Met alleviated the injury of OC cells induced by cDDP. (A-B) The level of DNA damage protein was detected by met combined with cDDP and met alone in A2780 and C13* cells. (C) IF showed the expression and localization of DNA damage protein in C13* cells, scale bars = 20 μm. (D) Comet assay, scale bars = 5 μm. **P<0.01 vs. control. Con, control; met, metformin; cDDP, cisplatin.

Fig. 2

3.3 Met contributed to drug resistance in OC cells against cDDP by affecting the ATM/CHK2 pathway

To explore the mechanism of cDDP resistance in OC induced by met, we further investigated how tumor cells respond to the combination of met and cDDP. ATM is a critical component of the cell's response to DNA damage, particularly in the case of DSBs [35]. When cancer cells encounter DSB, ATM kinases become activated and phosphorylate CHK2, which then plays a role in the cell's response to DSBs [36]. Therefore, we also observed the effect of met combined with cDDP on the ATM/CHK2 pathway. The results indicated that met increased the expression levels of phosphorylated ATM (p-ATM) and phosphorylated CHK2 (p-CHK2) proteins, while the combination of met with cDDP reduced their expression (Fig. 3A,B). The same trend was observed in C13* cells as well (Fig. 3C). Importantly, pre-treatment and simultaneous treatment did not affect the final outcome of the experiment (Fig. 3D). These findings suggested that met combined with cDDP diminished the sensitivity of OC cells to cDDP through modulation of the ATM/CHK2 pathway, contributing to drug resistance in OC cells against cDDP.Fig. 3 Met affected the sensitivity of OC cells to cDDP through the ATM/CHK2 pathway. (A) The A2780 cells were treated with met and cDDP or met alone. (B) The A2780 cells were treated with met alone. (C) The C13* cells were treated with met and cDDP or met alone. (D) The cells were treated with met for 24 hours and then combined with cDDP for 24 hours.

Fig. 3

3.4 Met alleviated the inhibitory effect of cDDP on tumor growth

To further investigate the impact of combining met with cDDP on tumor development, we established a C13* tumor-bearing mouse model in vivo and treated it with either cDDP alone or a combination of met and cDDP. Our findings revealed that the combination of met and cDDP led to a significant increase in both tumor volume and weight compared to met alone (Fig. 4A-B, P<0.05). Additionally, the combination treatment upregulated the expression levels of Ki-67 and Rad51 proteins, while significantly reducing the levels of c-Caspase3, p-ATM, and p-CHK2 proteins (Fig. 4C). These results suggested that met weakened the inhibitory effect of cDDP on tumor growth, promoted proliferation, and inhibited apoptosis in OC tissues. Moreover, it mitigated DNA damage induced by cDDP by decreasing ATM/CHK2 protein levels and enhanced the repair of DNA damage caused by cDDP through the upregulation of Rad51 protein expression. Consequently, these led to cDDP resistance in OC.Fig. 4 Met reduced the inhibitory effect of cDDP on tumor growth. (A) The tumor volume. (B) The tumor weight. C The protein levels of Ki-67, Caspase3, Rad51, p-ATM, and p-CHK2 (×100) were detected by IHC. cDDP, n = 5 (Unfortunately, one of them died during administration); met + cDDP, n = 5. Mean ± SEM. *P<0.05.

Fig. 4

3.5 ATM blocker ATMi-KU55933 reversed drug resistance of OC cells induced by met combined with cDDP

The aforementioned results demonstrated that met weakened the anti-tumor effect of cDDP both in vivo and in vitro, and this effect was associated with the ATM-CHK2 pathway. To further investigate this phenomenon, we conducted ATM blocking using KU55933 in C13* and A2780 cells, respectively, and observed the resulting cell apoptosis. The findings revealed that the inhibitory effect of met on apoptosis induced by cDDP was reversed upon administration of KU55933 (Fig. 5A-B, P<0.05). Furthermore, we established a mouse model treated with met in combination with cDDP and administered KU55933. In this model, the tumor weight and volume of mice treated with KU55933 decreased significantly (Fig. 5C-E, P<0.01), accompanied by a decrease in the protein levels of p-ATM, p-CHK2, and Ki-67, while an increase in c-Caspase3 (Fig. 5F). These results indicated that after administration of KU55933, the therapeutic effect of met combined with cDDP for OC treatment was significantly reversed, leading to increased apoptosis of OC cells. These findings further supported the involvement of the ATM/CHK2 pathway in the drug resistance of OC cells induced by the combination treatment. Moreover, intervention with ATM/CHK2 pathway could reverse the cDDP-resistance induced by the combination treatment.Fig. 5 KU55933 reversed the drug resistance induced by met and cDDP. (A) The apoptosis of C13* cells; (B) The apoptosis of A2780 cells. (C-D) The tumor weight and volume after ATM were interfered with in vitro. (E) The level and localization of p-ATM and p-CHK2, Ki-67, and c-Caspase3 proteins were detected by IHC after met combined with cDDP group and KU55933 plus the combination group (×100). Mean ± SEM, n = 5. *P<0.05, ***P<0.001. met, metformin; cDDP, cisplatin.

Fig. 5

4 Discussions

Met, a well-established medication for treating type II diabetes for over half a century, has demonstrated its utility in managing various conditions, including polycystic ovary syndrome, steatohepatitis, and cardiovascular disease, among others [37]. In OC, met alone has displayed the ability to impede the proliferation of drug-resistant OC cell lines such as A2780, CP70, C200, OV202, OVCAR3, SKVO3ip, PE01 and PE04 [16]. Our study further substantiated the beneficial impact of met alone in OC treatment by inducing apoptosis in drug-resistant OC cells C13* and A2780, underscoring its direct cytotoxic effect on these cells.

When combined with cDDP, previous studies have found that met usually has a synergistic effect with cDDP. In OC cell lines OVCAR-3 and OVCAR-4, met activated the ampk signal pathway and inhibit the mTOR pathway, thereby restraining their proliferation [38]. However, in other OC cell lines such as C13* and A2780 cells, our study demonstrated a reduction in γ-H2AX levels when met was combined with cDDP, indicating a decrease in DNA DSBs. This suggested that met increased the cDDP resistance of C13* and A2780 cells, meaning it reduced the sensitivity of tumor cells to chemotherapeutic drugs. A similar phenomenon had also been observed that met enhanced the sensitivity of the breast cancer cell line MCF-7 to chemotherapeutic drugs but had the opposite effect in SKBR3 [39]. Additionally, met-induced ampk activation promoted cisplatin resistance through PINK1/Parkin dependent mitophagy in gastric cancer [22]. Based on the data available in the literature and our findings, we found for the first time that not all types of OC cell lines were sensitive to met combined with chemotherapy drugs such as cDDP, and met did not necessarily work synergistically with chemotherapy for all tumors. This suggests that when using Met, a traditional medicine, for new applications such as treating ovarian cancer, it is necessary to proceed with caution.

In response to DNA-damaging agents, cells activate cell cycle checkpoints and a complex response network. ATM plays a critical role in the DNA damage response (DDR) process, primarily responding to DSBs and initiating downstream pathways activation through phosphorylation of target proteins at the site of DNA, including CHK2 [40]. When cDDP induced DDR in OC cells, drug-resistant OC cells activated the ATM/CHK2 pathway in response to DDR. Previous studies have shown that met alone could activate the ATM/CHK2 pathway in different cancer cells, inhibiting proliferation in non-small cell lung cancer cells and esophageal cancer cells [41,42]. Our results also demonstrated that met alone activated the ATM/CHK2 pathway in OC cells. In contrast, the combination of met and cDDP reduced the activation of the ATM/CHK2 pathway, indicating that met reduced the DDR induced by cDDP. Rad51 also participates in DNA damage repair. A high level of Rad51 is associated with an increased DNA recombination rate and enhanced resistance to DNA damage caused by chemotherapy [43]. OC exhibits a high level of the Rad51 gene, and its increase often indicates a poor prognosis of OC and resistance to cisplatin and other chemotherapeutic drugs [44]. Previous studies have found that artesunate could make OC cells sensitive to cDDP by down-regulating Rad51 [45]. In current study, when met was combined with cDDP, the level of the Rad51 protein expression increased. Rad51 was an important factor contributing to the increased DNA damage repair in OC cells induced by met combined with cDDP, leading to cDDP resistance.

Met has been widely used, and its safety and tolerability in the management of diabetes have been fully verified for diabetic patients. Studies have indicated that type Ⅱ diabetes is associated with an increased risk of liver cancer, pancreatic cancer, colon cancer, endometrial cancer, breast cancer, and bladder cancer [46]. Met is an independent protective factor against cancer risk in patients with type Ⅱ diabetes [47]. Furthermore, some studies suggest that in diabetic patients, the use of met reduces the risk of certain cancers and all-cause mortality, and it is associated with significant improvement in the prognosis of colon cancer and increases the survival rates of lung cancer [[48], [49], [50]]. However, these data are not fully supported. Randomized trials of met in the treatment of type Ⅱ diabetes and as an adjunctive therapy for various cancers (advanced or metastatic) have not found a reduction in cancer incidence or outcomes [51,52]. For instance, in breast cancer, met does not reduce the risk of breast cancer in diabetic patients [53]. Moreover, it has been found that met promotes the survival of dormant ER (+) breast cancer cells by activating the AMPK pathway [54]. In this study, the combined use of met and cDDP also showed suboptimal results. This suggests that the use of met in diabetic cancer patients pose risks. Therefore, more large-scale, long-term clinical trials are needed to verify the specific efficacy and safety of met in diabetic cancer patients.

Overall, the combination of met and cDDP induced chemo-resistance in OC cells, particularly in C13* and A2780 cell lines. The effect might be attributed to two mechanisms. Firstly, it reduced the occurrence of DSB in OC cells induced by cDDP through the ATM/CHK2 pathway. Secondly, it increased the repair of DSB in OC cells by the upregulation of Rad51 protein expression (Fig. 6).Fig. 6 The synergistic effect of the two mechanisms led to cDDP-resistance in OC cells induced by met combined with cisplatin.

Fig. 6

In the present study, we first demonstrated in A2780 and C13* cell lines that met alone increased apoptosis, but when combined with cDDP, it led to a decrease in apoptosis. Furthermore, we found that met combined with cDDP reduced the injury of OC cells induced by cDDP, decreased cell apoptosis and increased proliferation of OC cells. It reduced DNA damage of OC cells by inhibiting the ATM/CHK2 pathway, increased DNA damage and repair by increasing Rad51 protein expression, and ultimately mediated cDDP resistance in OC cells. These findings enhanced our understanding of met combined with chemotherapeutic drugs, and we first discovered that the combination of met and cDDP also had negative effect on cDDP treatment in certain OC cells.

CRediT authorship contribution statement

Jingjing Zhang: Writing – review & editing, Writing – original draft, Investigation. Ping Zhou: Formal analysis, Investigation, Writing – original draft. Tiancheng Wu: Writing – original draft, Investigation, Formal analysis, Data curation. Liping Zhang: Investigation, Data curation. Jiaqi Kang: Investigation, Formal analysis, Data curation. Jing Liao: Supervision, Funding acquisition. Daqiong Jiang: Supervision. Zheng Hu: Methodology, Funding acquisition, Data curation, Conceptualization. Zhiqiang Han: Project administration, Supervision. Bo Zhou: Writing – review & editing, Writing – original draft, Investigation, Formal analysis, Data curation, Conceptualization.

Declaration of competing interest

We declare the manuscript is an original work which has not been previously published in whole or in part and is not under consideration for publication in any other journals. Its publication has been approved by all co-authors. All authors have contributed to this work and state no existing competing interests.

Acknowledgments

We would like to extend our sincerest thanks to all the members who participated in the data acquisition, writing, and revision of this article. This study was supported by the 10.13039/501100001809 National Natural Science Foundation of China (Grant No. 32171465 , 82102392 and 32371541 ), 10.13039/501100003819 Natural Science Foundation of Hubei Province (Grant No. 2022CFB209 ), the Regional Joint Fund Project of Guangdong Basic and Applied Basic Research Foundation of China (Regional Cultivation Proiect, Grant No. 2021B1515140063), the Dongguan Social Development Key Proiect of China (Grant No. 20221800905772).
==== Refs
References

1 Lheureux S Gourley C Vergote I Oza AM. Epithelial ovarian cancer Lancet 393 10177 2019 1240 1253 10.1016/s0140-6736(18)32552-2 30910306
2 Webb PM Jordan SJ. Epidemiology of epithelial ovarian cancer Best Pract. Res. Clin. Obstet. Gynaecol. 41 2017 3 14 10.1016/j.bpobgyn.2016.08.006 27743768
3 Cummings M Nicolais O Shahin M. Surgery in advanced ovary cancer: primary versus interval cytoreduction Diagnostics 12 4 2022 10.3390/diagnostics12040988
4 Morand S Devanaboyina M Staats H Stanbery L Nemunaitis J. Ovarian cancer immunotherapy and personalized medicine Int. J. Mol. Sci. 22 12 2021 10.3390/ijms22126532
5 Kehoe S Hook J Nankivell M Jayson GC Kitchener H Lopes T Luesley D Perren T Bannoo S Mascarenhas M Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial Lancet 386 9990 2015 249 257 10.1016/s0140-6736(14)62223-6 26002111
6 Nachtigal MW Altman AD Arora R Schweizer F Arthur G. The potential of novel lipid agents for the treatment of chemotherapy-resistant human epithelial ovarian cancer Cancers 14 14 2022 10.3390/cancers14143318
7 Cen K Chen M He M Li Z Song Y Liu P Jiang Q Xu S Jia Y Shen P. Sporoderm-Broken spores of ganoderma lucidum sensitizes ovarian cancer to cisplatin by ROS/ERK signaling and attenuates chemotherapy-related toxicity Front. Pharmacol. 13 2022 826716 10.3389/fphar.2022.826716
8 Galluzzi L Senovilla L Vitale I Michels J Martins I Kepp O Castedo M Kroemer G. Molecular mechanisms of cisplatin resistance Oncogene 31 15 2012 1869 1883 10.1038/onc.2011.384 21892204
9 Yang L Xie HJ Li YY Wang X Liu XX Mai J. Molecular mechanisms of platinum‑based chemotherapy resistance in ovarian cancer (Review) Oncol. Rep. 47 4 2022 10.3892/or.2022.8293
10 Ledermann JA Drew Y Kristeleit RS. Homologous recombination deficiency and ovarian cancer Eur. J. Cancer 60 2016 49 58 10.1016/j.ejca.2016.03.005 27065456
11 Gamarra-Luques CD Goyeneche AA Hapon MB Telleria CM. Mifepristone prevents repopulation of ovarian cancer cells escaping cisplatin-paclitaxel therapy BMC Cancer 12 2012 200 10.1186/1471-2407-12-200 22642877
12 Guan LY Lu Y. New developments in molecular targeted therapy of ovarian cancer Discovery Med. 26 144 2018 219 229
13 Nishida M Yamashita N Ogawa T Koseki K Warabi E Ohue T Komatsu M Matsushita H Kakimi K Kawakami E Mitochondrial reactive oxygen species trigger metformin-dependent antitumor immunity via activation of Nrf2/mTORC1/p62 axis in tumor-infiltrating CD8T lymphocytes J. Immunother. Cancer 9 9 2021 10.1136/jitc-2021-002954
14 Xie J Xia L Xiang W He W Yin H Wang F Gao T Qi W Yang Z Yang X Metformin selectively inhibits metastatic colorectal cancer with the KRAS mutation by intracellular accumulation through silencing MATE1 Proc. Nat. Acad. Sci. USA 117 23 2020 13012 13022 10.1073/pnas.1918845117 32444490
15 Brown JR Chan DK Shank JJ Griffith KA Fan H Szulawski R Yang K Reynolds RK Johnston C McLean K Phase II clinical trial of metformin as a cancer stem cell-targeting agent in ovarian cancer JCI insight 5 11 2020 10.1172/jci.insight.133247
16 Rattan R Giri S Hartmann LC Shridhar V. Metformin attenuates ovarian cancer cell growth in an AMP-kinase dispensable manner J. Cell. Mol. Med. 15 1 2011 166 178 10.1111/j.1582-4934.2009.00954.x 19874425
17 Jafarzadeh E Montazeri V Aliebrahimi S Sezavar AH Ghahremani MH Ostad SN. Combined regimens of cisplatin and metformin in cancer therapy: a systematic review and meta-analysis Life Sci. 304 2022 120680 10.1016/j.lfs.2022.120680
18 Gulati S Desai J Palackdharry SM Morris JC Zhu Z Jandarov R Riaz MK Takiar V Mierzwa M Gutkind JS Phase 1 dose-finding study of metformin in combination with concurrent cisplatin and radiotherapy in patients with locally advanced head and neck squamous cell cancer Cancer 126 2 2020 354 362 10.1002/cncr.32539 31626727
19 Quattrini I Conti A Pazzaglia L Novello C Ferrari S Picci P Benassi MS. Metformin inhibits growth and sensitizes osteosarcoma cell lines to cisplatin through cell cycle modulation Oncol. Rep. 31 1 2014 370 375 10.3892/or.2013.2862 24253938
20 Zhou W Kavelaars A Heijnen CJ. Metformin prevents cisplatin-induced cognitive impairment and brain damage in mice PLoS One 11 3 2016 e0151890 10.1371/journal.pone.0151890
21 Li J Gui Y Ren J Liu X Feng Y Zeng Z He W Yang J Dai C. Metformin protects against cisplatin-induced tubular cell apoptosis and acute kidney injury via AMPKΑ-regulated autophagy induction Sci. Rep. 6 2016 23975 10.1038/srep23975 27052588
22 Xiao YY Xiao JX Wang XY Wang T Qu XH Jiang LP Tou FF Chen ZP Han XJ. Metformin-induced AMPK activation promotes cisplatin resistance through PINK1/Parkin dependent mitophagy in gastric cancer Front. Oncol. 12 2022 956190 10.3389/fonc.2022.956190
23 Janjetovic K Vucicevic L Misirkic M Vilimanovich U Tovilovic G Zogovic N Nikolic Z Jovanovic S Bumbasirevic V Trajkovic V Metformin reduces cisplatin-mediated apoptotic death of cancer cells through AMPK-independent activation of Akt Eur. J. Pharmacol. 651 1-3 2011 41 50 10.1016/j.ejphar.2010.11.005 21114978
24 Liu SH Yu J Creeden JF Sutton JM Markowiak S Sanchez R Nemunaitis J Kalinoski A Zhang JT Damoiseaux R Repurposing metformin, simvastatin and digoxin as a combination for targeted therapy for pancreatic ductal adenocarcinoma Cancer Lett. 491 2020 97 107 10.1016/j.canlet.2020.08.002 32829010
25 Asselin E Mills GB Tsang BK. XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells Cancer Res. 61 5 2001 1862 1868 11280739
26 Weng D Song X Xing H Ma X Xia X Weng Y Zhou J Xu G Meng L Zhu T Implication of the Akt2/survivin pathway as a critical target in paclitaxel treatment in human ovarian cancer cells Cancer Lett. 273 2 2009 257 265 10.1016/j.canlet.2008.08.027 18842333
27 Sun C Li N Yang Z Zhou B He Y Weng D Fang Y Wu P Chen P Yang X miR-9 regulation of BRCA1 and ovarian cancer sensitivity to cisplatin and PARP inhibition J. Natl. Cancer Inst. 105 22 2013 1750 1758 10.1093/jnci/djt302 24168967
28 Porter AG Jänicke RU. Emerging roles of caspase-3 in apoptosis Cell Death Differ. 6 2 1999 99 104 10.1038/sj.cdd.4400476 10200555
29 Ruvolo PP Deng X May WS. Phosphorylation of Bcl2 and regulation of apoptosis Leukemia 15 4 2001 515 522 10.1038/sj.leu.2402090 11368354
30 Kinner A Wu W Staudt C Iliakis G. Gamma-H2AX in recognition and signaling of DNA double-strand breaks in the context of chromatin Nucleic Acids Res. 36 17 2008 5678 5694 10.1093/nar/gkn550 18772227
31 Lau CH Seow KM Chen KH. The molecular mechanisms of actions, effects, and clinical implications of PARP inhibitors in epithelial ovarian cancers: a systematic review Int. J. Mol. Sci. 23 15 2022 10.3390/ijms23158125
32 Bonilla B Hengel SR Grundy MK Bernstein KA. RAD51 gene family structure and function Annu. Rev. Genet. 54 2020 25 46 10.1146/annurev-genet-021920-092410 32663049
33 Chen H Zhang L Zuo M Lou X Liu B Fu T. Inhibition of apoptosis through AKT-mTOR pathway in ovarian cancer and renal cancer Aging 15 4 2023 1210 1227 10.18632/aging.204564 36849137
34 Yung MM Ngan HY Chan DW. Targeting AMPK signaling in combating ovarian cancers: opportunities and challenges Acta Biochim. Biophy. Sin. 48 4 2016 301 317 10.1093/abbs/gmv128
35 Maréchal A Zou L. DNA damage sensing by the ATM and ATR kinases Cold Spring Harb. Perspect. Biol. 5 9 2013 10.1101/cshperspect.a012716
36 Sancar A Lindsey-Boltz LA Unsal-Kaçmaz K Linn S. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints Annu. Rev. Biochem. 73 2004 39 85 10.1146/annurev.biochem.73.011303.073723 15189136
37 Foretz M Guigas B Viollet B. Metformin: update on mechanisms of action and repurposing potential Nature Rev. Endocrinol. 19 8 2023 460 476 10.1038/s41574-023-00833-4 37130947
38 Gotlieb WH Saumet J Beauchamp MC Gu J Lau S Pollak MN Bruchim I. In vitro metformin anti-neoplastic activity in epithelial ovarian cancer Gynecol. Oncol. 110 2 2008 246 250 10.1016/j.ygyno.2008.04.008 18495226
39 Fatehi R Rashedinia M Akbarizadeh AR Zamani M Firouzabadi N. Metformin enhances anti-cancer properties of resveratrol in MCF-7 breast cancer cells via induction of apoptosis, autophagy and alteration in cell cycle distribution Biochem. Biophys. Res. Commun. 644 2023 130 139 10.1016/j.bbrc.2022.12.069 36641965
40 Zuco V Benedetti V Zunino F. ATM- and ATR-mediated response to DNA damage induced by a novel camptothecin, ST1968 Cancer Lett. 292 2 2010 186 196 10.1016/j.canlet.2009.12.001 20042274
41 Storozhuk Y Hopmans SN Sanli T Barron C Tsiani E Cutz JC Pond G Wright J Singh G Tsakiridis T. Metformin inhibits growth and enhances radiation response of non-small cell lung cancer (NSCLC) through ATM and AMPK Br. J. Cancer 108 10 2013 2021 2032 10.1038/bjc.2013.187 23632475
42 Feng T Li L Ling S Fan N Fang M Zhang H Fang X Lan W Hou Z Meng Q Metformin enhances radiation response of ECa109 cells through activation of ATM and AMPK Biomed. Pharmacother. 69 2015 260 266 10.1016/j.biopha.2014.11.021 25661368
43 Yang Z Waldman AS Wyatt MD. Expression and regulation of RAD51 mediate cellular responses to chemotherapeutics Biochem. Pharmacol. 83 6 2012 741 746 10.1016/j.bcp.2011.12.022 22222428
44 Feng Y Wang D Xiong L Zhen G Tan J. Predictive value of RAD51 on the survival and drug responsiveness of ovarian cancer Cancer Cell Int. 21 1 2021 249 10.1186/s12935-021-01953-5 33952262
45 Wang B Hou D Liu Q Wu T Guo H Zhang X Zou Y Liu Z Liu J Wei J Artesunate sensitizes ovarian cancer cells to cisplatin by downregulating RAD51 Cancer Biol. Ther. 16 10 2015 1548 1556 10.1080/15384047.2015.1071738 26176175
46 McFarland MS Cripps R. Diabetes mellitus and increased risk of cancer: focus on metformin and the insulin analogs Pharmacotherapy 30 11 2010 1159 1178 10.1592/phco.30.11.1159 20973689
47 Zhang K Bai P Dai H Deng Z. Metformin and risk of cancer among patients with type 2 diabetes mellitus: a systematic review and meta-analysis Primary Care Diabetes 15 1 2021 52 58 10.1016/j.pcd.2020.06.001 32605879
48 Henderson D Frieson D Zuber J Solomon SS. Metformin has positive therapeutic effects in colon cancer and lung cancer Am. J. Med. Sci. 354 3 2017 246 251 10.1016/j.amjms.2017.05.006 28918830
49 Tarhini Z Manceur K Magne J Mathonnet M Jost J Christou N. The effect of metformin on the survival of colorectal cancer patients with type 2 diabetes mellitus Sci. Rep. 12 1 2022 12374 10.1038/s41598-022-16677-3 35859114
50 Bo S Benso A Durazzo M Ghigo E. Does use of metformin protect against cancer in type 2 diabetes mellitus? J. Endocrinol. Invest. 35 2 2012 231 235 10.1007/bf03345423 22490993
51 Yu OHY Suissa S. Metformin and cancer: solutions to a real-world evidence failure Diabetes Care 46 5 2023 904 912 10.2337/dci22-0047 37185680
52 Smiechowski BB Azoulay L Yin H Pollak MN Suissa S. The use of metformin and the incidence of lung cancer in patients with type 2 diabetes Diabetes Care 36 1 2013 124 129 10.2337/dc12-0740 22923670
53 Lu Y Hajjar A Cryns VL Trentham-Dietz A Gangnon RE Heckman-Stoddard BM Alagoz O. Breast cancer risk for women with diabetes and the impact of metformin: a meta-analysis Cancer Med. 12 10 2023 11703 11718 10.1002/cam4.5545 36533539
54 Hampsch RA Wells JD Traphagen NA McCleery CF Fields JL Shee K Dillon LM Pooler DB Lewis LD Demidenko E AMPK activation by metformin promotes survival of dormant ER(+) breast cancer cells Clinical Cancer Res. 26 14 2020 3707 3719 10.1158/1078-0432.Ccr-20-0269 32321715
